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Interaction between diabetic status and lesion complexity for 1-year safety
and efﬁcacy outcomes
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Efﬁcacy
endpoints
TLR 4.6% 4.8% 0.96
(0.64,1.44
8.0% 4.5% 1.80
(1.39,2.33)
0.01
TVR 7.4% 6.8% 1.13
(0.81, 1.58)
10.6% 5.9% 1.81
(1.45, 2.27)
0.02
Safety
endpoints
Cardiac
dearh or MI
3.6% 2.1% 1.71 (1.00-
2;93)
5.7% 4.7% 1.22
(0.93,1.60)
0.28
Stent
Thrombosis
0.7% 0.3% 2.32 (0.60,
8.97)
1.7% 0.9% 1.87 (1.05,
3.32)
0.78
Independent Predictors of Stent Thrombosis at 1 Year
HR 95% CI p Value
Clinical variables
Hypertension 3.93 1.53 – 10.12 0.005
STEMI vs NSTEMI/
UA
2.72 1.46 – 5.06 0.002
History of
peripheral vascular
disease
2.18 1.05 – 4.51 0.040
Angiographic/
procedural
variables
Ejection fraction
40%
2.41 1.15 – 5.00 0.020
IVUS-guided
stenting
0.49 0.24 – 0.90 0.045
Later vs early
generation DES
0.54 0.29 – 1.00 0.050
Other variables
Premature DAPT
discontinuation
5.16 2.57 – 10.34 <0.001
VerifyNow P2Y12
PRU >208
2.92 1.57 – 5.42 <0.001
Separate Cox models were used for clinical, angiographic/procedural, and other variables
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SConclusions: ST within 1 year occurs inw1% of ACS patients treated with DES and
is associated with high rates of myocardial infarction and mortality. Strategies that
may reduce ST in ACS patients include the use of more potent ADP antagonists, better
strategies to achieve DAPT adherence, the use of later generation DES, and optimi-
zation of post-stent results with IVUS.
TCT-19
The Impact of Coronary Lesion Severity on Drug-eluting Stent Outcomes
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Background: Previous studies have shown conﬂicting results in regard to efﬁcacy
outcomes of drug-eluting stents (DES) in patients with and without diabetes mellitus
(DM). Little is known on the impact of baseline lesion complexity on clinical
outcomes in these patients.
Methods: Patient-level data from 18 prospective randomized DES trials were pooled
(ACUITY; COMPARE; C-SIRIUS; ENDEAVOR 2; ENDEAVOR 3; ENDEAVOR
4; E-SIRIUS; HORIZONS-AMI; RAVEL; SIRIUS; SPIRIT 2; SPIRIT 3; SPIRIT 4;
TAXUS 1; TAXUS 2; TAXUS 4; TAXUS 5; TAXUS 6). Propensity-adjusted
outcomes according to the presence of DM and lesion complexity (ACC/AHA class
A/B1 vs. B2/C).
Results: Among 18,441 randomized patients, 3,467 (19%) had DM. Pts with vs.
without DM had higher 1-year rates of TLR (HR [95%CI] ¼ 1.34 [1.05, 1.70]), TVR
(HR [95%CI] ¼ 1.40 [1.15, 1.72]) and TVR non-TLR (HR [95%CI] ¼ 1.62 [1.14,
2.31). The 1-year rates of cardiac death or myocardial infarction (MI) were also higher
in DM (HR [95%CI] ¼ 1.40 [1.09, 1.81]). As shown in the Table, an interaction was
present between DM status and ACC/AHA lesion class on the need for repeat
revascularization after DES. There was no interaction between DM status and ACC/
AHA lesion class on safety endpoints.
Conclusions: In the DES era, the rates of TLR and TVR after PCI of non-complex
lesions are similar in DM and non-DM patients, whereas complex lesions still have
higher repeat revascularization rates if DM is present. Compared to non-DM, DM
patients continue to have higher rates of clinical restenosis in complex lesions, and of
cardiac death and MI in all patients. Despite advances in DES, new strategies are
needed for the diabetic patient.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-20
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with De Novo Native Coronary Artery Lesions: The TARGET I Trial
Bo Xu1, Run-Lin Gao1, Alexandra Lansky2, Yuejin Yang1, Ma Changsheng3,
Yaling Han4, Shao Liang Chen5, Hui Li6, Ruiyan Zhang7, Guosheng Fu8, Zuyi Yuan9,
Yong Huo10, Wei Li11, Yelin Zhao1, Martin Leon12
1Fu Wai Hospital, National Center for Cardiovascular Diseases, China, Beijing,
China, 2Yale University School of Medicine, New Haven, United States, 3Afﬁliated
Anzhen Hospital of Capital Medical University, Beijing, China, 4Shenyang Northern
Hospital, Shenyang, China, 5Nanjing First Hospital, Nanjing Medical University,
Nanjing, China, 6Daqing Oil Field General Hospital, Daqing, China, 7Afﬁliated
Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai,
China, 8Afﬁliated SRRS Hospital of Zhejiang University School of Medicine,
Hangzhou, China, 9First Afﬁliated Hospital of Xi’an Jiaotong University School of
Medicine, Xi'an, China, 10Peking University First Hospital, Beijing, China, 11National
Center for Cardiovascular Diseases of China, Beijing, China, 12Columbia University
Medical Center / Cardiovascular Research Foundation, New York, NY
Background: This article reports the 2-year clinical outcomes of the abluminal
groove-ﬁlled biodegradable polymer sirolimus-eluting stent (SES) FIREHAWK
(MicroPort Medical, Shanghai, China) compared with the everolimus-eluting stent
(EES) XIENCE V in the randomized TARGET I trial.
Methods: A total of 458 patients with single de novo native coronary lesions
<¼24 mm in length and a coronary artery >¼2.25 to <¼4.0 mm in diameter were
enrolled in the TARGET I study, a prospective, randomized, non-inferiority trial. The
primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The
secondary endpoint, target lesion failure (TLF), was deﬁned as the composite of
cardiac death, target vessel myocardial infarction (TVMI), or ischemia-driven target
lesion revascularization (iTLR). Clinical follow-up was scheduled at 1-, 6- and 12-
month, and annually up to 5 years for all enrolled patients. All adverse clinical events
were adjudicated by an independent committee.
Results: The 9-month in-stent LLL of the FIREHAWK was comparable to the
XIENCE V group (0.130.24 mm vs. 0.130.18 mm, p¼0.94; difference and 95%
conﬁdence interval 0.00 [-0.04, 0.04] mm; p for non-inferiority <0.0001). After 2
years, the TLF rates were 2.7% and 2.6% in FIREHAWK and XIENCE V group,
respectively (p ¼ 0.97). Between 1 year and 2 years, only 1 new iTLR was occurred
in each group, with no additional cardiac death and TVMI. No deﬁnite / probable
stent thrombosis was observed in both groups at 2 years. The major results are shown
in the table.acts/ORAL/Bare Metal and Drug-Eluting Stents B7
Table. Clinical Outcomes at 12 Months Stratiﬁed According to rSS and bSS
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ID-TVF, n (%) 16 (2.87) 28 (4.31) 63 (9.75) 0.1811 0.0001 <0.0001 <0.0001
Cardiac Death,
n (%)
0 (0.00) 3 (0.46) 6 (0.93) 0.2536 0.3411 0.0334 0.0661
TVMI, n (%) 8 (1.43) 19 (2.93) 34 (5.26) 0.0802 0.0339 0.0003 0.0008
ID-TVR, n (%) 8 (1.43) 7 (1.08) 30 (4.64) 0.5787 0.0001 0.0015 <0.0001
Residual Syntax
score
Low (rSS¼0) Mid
(0<rSS<¼5)
High (rSS>5) p-Value
n¼1190 n¼403 n¼258 * Low vs. Mid * Mid vs. High * Low vs. High All Groups
ID-TVF, n (%) 52 (4.37) 28 (6.95) 26 (10.08) 0.0405 0.1518 0.0002 0.0008
Cardiac Death,
n (%)
2 (0.17) 3 (0.74) 4 (1.55) 0.1064 0.4406 0.0110 0.0091
TVMI, n (%) 27 (2.27) 17 (4.22) 17 (6.59) 0.0390 0.1783 0.0002 0.0010
ID-TVR, n (%) 25 (2.10) 9 (2.23) 10 (3.88) 0.8737 0.2176 0.0924 0.2317
* p value <0.0167 was considered statistically signiﬁcant.
Table. Clinical Outcomes at 1- and 2-Year
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Clinical Follow-Up,
% (n)
99.6 (226) 100 (231) 0.50 99.6 (226) 100 (231) 0.50
Dual Antiplatelet
Therapy,
% (n/N)
92.4 (208/225) 93.0
(213/229)
0.82 24.9
(56/225)
27.8
(63/227)
0.49
Death, % (n) 0.4 (1) 0.9 (2) 1.00 0.4 (1) 0.9 (2) 1.00
Cardiac Death 0.4 (1) 0 (0) 1.00 0.4 (1) 0 (0) 1.00
Non Cardiac Death 0 (0) 0.9 (2) 0.50 0 (0) 0.9 (2) 0.50
Myocardial
Infarction, % (n)
1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50
Q Wave MI 0 (0) 0 (0) - 0 (0) 0 (0) -
Non Q Wave MI 1.3 (3) 2.2 (5) 0.72 1.3 (3) 2.6 (6) 0.50
Target Vessel MI 1.3 (3) 1.7 (4) 1.00 1.3 (3) 1.7 (4) 1.00
Ischemia-Driven
TLR, % (n)
0.4 (1) 0.4 (1) 1.00 0.9 (2) 0.9 (2) 1.00
Any
Revascularization,
% (n)
1.8 (4) 4.8 (11) 0.07 2.2 (5) 6.1 (14) 0.04
*Device-Oriented
Composite
Endpoint (TLF), %
(n)
2.2 (5) 2.2 (5) 1.00 2.7 (6) 2.6 (6) 0.97
**Patient-Oriented
Composite
Endpoint, % (n)
3.5 (8) 7.4 (17) 0.07 4.0 (9) 8.7 (20) 0.04
Deﬁnite or
Probable Stent
Thrombosis, % (n)
0 (0) 0 (0) - 0 (0) 0 (0) -
*Device-Oriented Composite Endpoint (TLF) deﬁned as the composite of cardiac death, target
vessel MI, or ischemia-driven TLR.
**Patient-Oriented Composite Endpoint deﬁned as the composite of all cause death, all MI, or
any revascularization.
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SConclusions: In the multicenter TARGET I trial, the novel abluminal groove-ﬁlled
biodegradable polymer SES FIREHAWK was comparable to the durable polymer
EES XIENCE V with respect to the TLF and its components at two years for treating
patients with single de novo native coronary lesions. The incidences of clinical
endpoints were low in both groups. (ClinicalTrials.gov Identiﬁer: NCT01196819).
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Background: Previous studies demonstrated the safety and efﬁcacy of the 2nd
generation drug-eluting stent in treating patients with simple to complex coronary
lesions. The Syntax score has been proposed as a valuable tool to characterize the
coronary anatomy prospectively with respect to its complexity. However, the prog-
nostic value of baseline Syntax score (bSS) and residual Syntax score (rSS) in patients
with complex lesions treated by XIENCE V everolimus-eluting stent (Abbott
Vascular, Santa Clara, CA, USA) on adverse outcomes have not been validated.
Methods: SEEDS was a prospective, multicenter registry study designed to enroll up
to 1900 patients with small vessel (reference vessel diameter <¼ 2.75mm), long
lesion (length >¼ 25mm), or multivessel disease (>¼ 2 target vessels) suitable for
treatment with XIENCE V at 48 centers in China mainland, Macao and Taiwan. The
primary outcome was ischemia-driven target vessel failure (ID-TVF), deﬁned as the
composite of cardiac death, target vessel myocardial infarction (TVMI), or ischemia-
driven target vessel revascularization (ID-TVR) at 12 months. The bSS stratiﬁed
into low (<¼6), mid (>6 and <¼12) and high (>12) and rSS into low (<¼0), mid
(>0 and <¼5) and high (>5) tertiles were applied in all patients.
Results: The mean of bSS was 10.87  7.26, and after PCI the rSS was 2.18  3.97.
At 12 months the primary outcome ID-TVF and its components cardiac death, TVMI,
and ID-TVR were 5.95%, 0.47%, 3.32%, and 2.47%, respectively. The table shows
the clinical outcomes stratiﬁed according to rSS and bSS.B8 JACC Vol 62/18/Suppl B j October 27–NovembConclusions: Signiﬁcantly higher rates of 12-month ID-TVF were observed in the
highest baseline and residual Syntax score groups, indicating that baseline and
residual Syntax score might be the useful tools to predict clinical outcomes in complex
patients treating with 2nd generation everolimus-eluting stent (ClinicalTrials.gov
identiﬁer: NCT 01157455).Bifurcation and Left Main Stenting
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Background: In bifurcation lesions (15-20% of PCIs), results of PCI with balloon
expandable stents are often impaired by carina incomplete support, strut deformation,
malapposition, or excessive metallic burden when treated with 2 stents. Dedicated
stents were developed but they often require precise and difﬁcult positioning or
require to stent ﬁrst the side branch. There is thus a need for an easy to use stent in
most bifurcations and which follows guideline practice of main branch (MB) provi-
sional stenting, supporting carina with minimal disruption of the side branch (SB)
anatomy. The self-expanding STENTYS DES (Stentys, Paris, France) has dis-
connectable struts for side branch access and showed very high procedural success and
low MACE rate in the OPEN I trial.
Methods: The OPEN II prospective, multi-centric single-arm study assess the safety
and efﬁcacy at 6 and 12-months of the STENTYS Paclitaxel eluting stent in routine
coronary bifurcation stenosis. Key exclusion criteria were Medina class 0,0,1, chronic
total occlusion, unprotected left main, and STEMI as clinical presentation. SB stenting
was left to operator's discretion. The primary endpoint of the study is MACE at 6
months follow-up. Secondary endpoints include MACE rate at 12 months, targeter 1, 2013 j TCT Abstracts/ORAL/Bifurcation and Left Main Stenting
